FdaApplication
NDA 202343
Identifiers
- fda_app_no: NDA202343
Properties
| Property | Value |
|---|---|
| applicant_name | MERCK SHARP AND DOHME CORP |
| application_type | NDA |
| approval_date | 2011-10-07 |
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| JUVISYNC | SIMVASTATIN; SITAGLIPTIN PHOSPHATE | 10MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| JUVISYNC | SIMVASTATIN; SITAGLIPTIN PHOSPHATE | 20MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| JUVISYNC | SIMVASTATIN; SITAGLIPTIN PHOSPHATE | 40MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| JUVISYNC | SIMVASTATIN; SITAGLIPTIN PHOSPHATE | 20MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| JUVISYNC | SIMVASTATIN; SITAGLIPTIN PHOSPHATE | 40MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
| JUVISYNC | SIMVASTATIN; SITAGLIPTIN PHOSPHATE | 10MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET;ORAL |
6 products